Blackstone Inc’s United Therapeutics UTHR Stock Holding History

Blackstone Inc’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-55,813	Closed	-$6.55M	–	107
2019 Q1	$6.55M	Buy	+55,813	New	+$6.5M	0.03%	49

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Blackstone Inc's UTHR Position: Q2 2019 in Review

Blackstone Inc sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 55,813 shares — an estimated $6.55M sold.

Blackstone Inc first reported a position in UTHR in Q1 2019 and held it in 1 quarter. The position peaked at $6.55M in Q1 2019. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

Blackstone Inc reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
Blackstone Inc sold 55,813 United Therapeutics shares in Q2 2019, an estimated $6.55M.
Blackstone Inc first reported a position in United Therapeutics in Q1 2019 and held it in 1 quarter.
Blackstone Inc's United Therapeutics position peaked at $6.55M in Q1 2019.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Blackstone Inc's 13F filing for Q2 2019, filed 14 Aug 2019.